Cargando…

β-Cell Function Preservation After 3.5 Years of Intensive Diabetes Therapy

OBJECTIVE: To assess β-cell function preservation after 3.5 years of intensive therapy with insulin plus metformin (INS group) versus triple oral therapy (TOT group) with metformin, glyburide, and pioglitazone. RESEARCH DESIGN AND METHODS: This was a randomized trial of 58 patients with treatment-na...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harrison, Lindsay B., Adams-Huet, Beverley, Raskin, Philip, Lingvay, Ildiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3379585/ https://www.ncbi.nlm.nih.gov/pubmed/22723578 http://dx.doi.org/10.2337/dc11-2170

Ejemplares similares

Response to Comment on: Harrison et al. β-Cell Function Preservation After 3.5 Years of Intensive Diabetes Therapy. Diabetes Care 2012;35:1406–1412
por: Harrison, Lindsay B., et al.
Publicado: (2013)

Insulin-Based Versus Triple Oral Therapy for Newly Diagnosed Type 2 Diabetes: Which is better?
por: Lingvay, Ildiko, et al.
Publicado: (2009)

Effect of medication adherence on clinical outcomes in type 2 diabetes: analysis of the SIMPLE study
por: Patel, Sapna, et al.
Publicado: (2019)

Comment on: Harrison et al. β-Cell Function Preservation After 3.5 Years of Intensive Diabetes Therapy. Diabetes Care 2012;35:1406–1412
por: Aizawa, Toru, et al.
Publicado: (2013)

Comparative Evaluation of Two Venous Sampling Techniques for the Assessment of Pancreatic Insulin and Zinc Release upon Glucose Challenge
por: Pillai, Anil Kumar, et al.
Publicado: (2015)

Effectiveness of Early Intensive Therapy on β-Cell Preservation in Type 1 Diabetes
por: Buckingham, Bruce, et al.
Publicado: (2013)

Ingredients for microbial life preserved in 3.5 billion-year-old fluid inclusions
por: Mißbach, Helge, et al.
Publicado: (2021)

Rapid Improvement in Diabetes After Gastric Bypass Surgery: Is it the diet or surgery?
por: Lingvay, Ildiko, et al.
Publicado: (2013)

Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy
por: Srivastava, Anand, et al.
Publicado: (2016)

Pediatric glaucoma suspects
por: Kooner, Karanjit, et al.
Publicado: (2014)

Correlates of Insulin Resistance in Nascent Metabolic Syndrome
por: Adams-Huet, Beverley, et al.
Publicado: (2023)

An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures
por: Lingvay, Ildiko, et al.
Publicado: (2017)

Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Comment on: Park et al. Association of Serum Ferritin and the Development of Metabolic Syndrome in Middle-Aged Korean Men: A 5-Year Follow-up Study. Diabetes Care 2012;35:2521–2526
por: Fumeron, Frédéric, et al.
Publicado: (2012)

Corrigendum to “Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy”
por: Neubecker, Katherine, et al.
Publicado: (2017)

Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment
por: Edwards, Khary, et al.
Publicado: (2023)

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
por: Rodbard, Helena W, et al.
Publicado: (2018)

Earliest signs of life on land preserved in ca. 3.5 Ga hot spring deposits
por: Djokic, Tara, et al.
Publicado: (2017)

Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy
por: Neubecker, Katherine, et al.
Publicado: (2011)

Increased Adipocyte Hypertrophy in Patients with Nascent Metabolic Syndrome
por: Jialal, Ishwarlal, et al.
Publicado: (2023)

Chronic Pancreatitis Associated With a Variant of CFTR Gene Treated With Total Pancreatectomy and Autologous Islet Cell Transplantation
por: Agarwal, Shubham, et al.
Publicado: (2023)

Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs)
por: Desouza, Cyrus, et al.
Publicado: (2020)

Statins and renal disease progression, ophthalmic manifestations, and neurological manifestations in veterans with diabetes: A retrospective cohort study
por: Mansi, Ishak A., et al.
Publicado: (2022)

3,5-Dimethylpyrazolium 3,5-dinitrosalicylate
por: Wei, Shuaishuai, et al.
Publicado: (2012)

OR03-1 Achievement of HbA1c <6.5% without weight gain and hypoglycemia in people with type 2 diabetes treated with tirzepatide across the phase 3 SURPASS program
por: Allen, Sheryl Elaine, et al.
Publicado: (2022)

Corrigendum: Earliest signs of life on land preserved in ca. 3.5 Ga hot spring deposits
por: Djokic, Tara, et al.
Publicado: (2017)

An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal–Bolus Insulin in Type 2 Diabetes
por: Lingvay, Ildiko, et al.
Publicado: (2022)

Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance
por: Almandoz, Jaime P., et al.
Publicado: (2020)

Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program
por: Lingvay, Ildiko, et al.
Publicado: (2023)

N-Benzyl-3,5-dideoxy-3,5-imino-1,2-O-isopropylidene-β-l-lyxofuranose
por: Edgeley, David S., et al.
Publicado: (2012)

Clinical efficacy of Enzyme Replacement Therapy in paediatric Hunter patients, an independent study of 3.5 years
por: Tomanin, Rosella, et al.
Publicado: (2014)

Level of knowledge of mothers (18-35 years of age) of under 5 children regarding ORS therapy
por: Divasha,, et al.
Publicado: (2020)

Introduction: 35 years on
por: Inglis, John R.
Publicado: (2023)

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
por: Husain, Mansoor, et al.
Publicado: (2020)

Early Intensive Insulin Use May Preserve β-Cell Function in Neonatal Diabetes Due to Mutations in the Proinsulin Gene
por: Letourneau, Lisa R., et al.
Publicado: (2017)

Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis
por: Lingvay, Ildiko, et al.
Publicado: (2020)

Geophysik, 3.5
por: Rawer, Karl
Publicado: (1976)

Compressor 3.5.
por: Gary, Brian
Publicado: (2010)

Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function
por: Herold, Kevan C., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6psdjh6r4okdftnhiuc8nb67cv